Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

SRR8942973

c32d09b9-f3d5-5937-858a-ba4ed7235113

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.300
  • MYC_TARGETS_V1+0.160
  • WNT_BETA_CATENIN_SIGNALING+0.150
  • PANCREAS_BETA_CELLS+0.140
  • TGF_BETA_SIGNALING+0.120
  • UV_RESPONSE_DN+0.110
  • ANDROGEN_RESPONSE+0.100
  • HEME_METABOLISM+0.040
  • OXIDATIVE_PHOSPHORYLATION+0.000
  • UNFOLDED_PROTEIN_RESPONSE-0.030

Top 10 suppressed

  • ANGIOGENESIS-0.460
  • INTERFERON_ALPHA_RESPONSE-0.450
  • IL6_JAK_STAT3_SIGNALING-0.430
  • CHOLESTEROL_HOMEOSTASIS-0.420
  • ESTROGEN_RESPONSE_LATE-0.410
  • ALLOGRAFT_REJECTION-0.400
  • COAGULATION-0.400
  • INTERFERON_GAMMA_RESPONSE-0.400
  • TNFA_SIGNALING_VIA_NFKB-0.390
  • INFLAMMATORY_RESPONSE-0.380

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1SRR12202455
bladder-landscape@3
0.874
2SRR8942980
bladder-landscape@3
0.873
3DRR168565
bladder-landscape@3
0.869
4MDT-AP-3207
medullo-epn-umap@date-based
MedMedulloblastoma0.865
5MNG1181
mng-umap@100
0.865
6MDT-AP-0395
medullo-epn-umap@date-based
MedMedulloblastoma0.864
7MDT-AP-1341
medullo-epn-umap@date-based
MedMedulloblastoma0.858
8MDT-AP-2991
medullo-epn-umap@date-based
MedMedulloblastoma0.856
9BS_SDCNP7MW
medullo-epn-umap@date-based
EPNEPN Tumor0.856
10TCGA-A7-A0DC-01A-11R-A00Z-07
breast-umap@18
D0.855

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 8 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.300Remibrutinib— uncovered
MYC_TARGETS_V10.160Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.150Inavolisib— uncovered
PANCREAS_BETA_CELLS0.140Cobimetinib— uncovered
TGF_BETA_SIGNALING0.120Inavolisib— uncovered
UV_RESPONSE_DN0.110Inavolisib— uncovered
ANDROGEN_RESPONSE0.100Inavolisib— uncovered
HEME_METABOLISM0.040Temsirolimus— uncovered